Join Our Mailing List:
Follow Us:
Shop Contact Us
You have 0  Item in Cart | View Cart
Featured Events
View All Events
Satiro N. De Oliveira, M.D.
Research performed at: UCLA's Jonsson Comprehensive Cancer Center
Specialty/Research Area: Hematology, Oncology, Stem Cell Transplantation
Award Year: 2017
Career Summary: Dr. Satiro De Oliveira is an Assistant Professor at the Division of Pediatric hematology/Oncology at UCLA, with clinical focus in hematopoietic stem cell transplantation and gene therapy. Graduated in Brazil at the Faculdade de Medicina de Ribeirao Preto, University of Sao Paulo, Dr. De Oliveira restarted his career as a physician scientist in the US completing fellowship at the Children’s Hospital Los Angeles and conducting research under the mentorship of Dr. Donald B. Kohn, developing protocols for gene modification of human hematopoietic stem cells, ex vivo culture of primary cells, and humanized mouse models. In his twenty-year career in Pediatrics, Dr. De Oliveira has dedicated his efforts to research as a path to improve patient outcomes. His research interests are cellular therapy, cancer immunotherapy and biology of hematopoietic stem cell transplantation. His work has been nationally recognized by awards such as the Today’s and Tomorrow’s Children Fund Award, the St. Baldrick’s Foundation Scholar Award, the Kure It Cancer Research Rivals United Award, and the Hope On Wheels Scholar Hope Grant Award.

Year STOP CANCER Award was received: 2017 STOP CANCER Research Career Development Award

Description of research performed: Dr. De Oliveira’s research approach proposes the innovative concept of using gene modification of hematopoietic stem cells to create multilineage immune effectors able to directly target malignant cells through the use of anti-CD19 chimeric antigen receptors (CAR). This approach is untested in clinical translation to this date, and implies harnessing a patient’s own blood stem cells to create a whole self-renewing immune system directed to destroy cancer, a concept that can be applied to different cancers just by adjusting the target specificity. 
Results of research: The prospect of modifying autologous cells to enhance graft-versus-cancer activity bears the possibility of decreased morbidity and mortality, being desirable for specifically vulnerable populations, as children and elderly patients, and offering alternative therapy for those without HLA-matched donors or umbilical cord units available for allogeneic HSCT, benefiting patients from ethnic minorities.

STOP CANCER is committed to funding the most promising and innovative scientists in their early research of all forms of cancer prevention, treatment, cures and subsequent clinical applications. STOP CANCER works primarily with local National Cancer Institute-designated Comprehensive Cancer Centers and other qualified institutions in the United States to carry out its mission.

Copyright © 2017 STOP CANCER. All Rights Reserved. | Privacy Policy